Abstract

BackgroundWe assessed the stability of BAFF, interferon, plasma cell and LDG neutrophil gene expression signatures over time, and whether changes in expression coincided with changes in SLE disease activity.MethodsTwo hundred forty-three patients with SLE were evaluated for disease activity, serological parameters and peripheral blood gene signatures in clinic visits (2 or more per patient) that occurred between 2009 and 2012. Levels of the BAFF gene transcript, plasma cell signature, Interferon (IFN) signature and the low density granulocytes (LDG)-associated neutrophil gene signature were assessed in PAX-gene-preserved peripheral blood by global microarray. The stability of repeated measures of gene expression was quantified using intra-class correlation coefficients. SLE disease activity was measured using the Physicians Global Assessment and the SELENA-SLEDAI index and its components. Using a mixed effects regression model we assessed: 1) the association between a patient’s average gene signature expression over time and disease activity, and 2) the association between a patient’s changes in gene expression over time and changes in disease activity.ResultsGene expression signatures showed more within-person stability than systolic blood pressure. The IFN signature exhibited the most stability. Patients with high levels of BAFF and IFN transcripts tended to have significantly higher levels of musculoskeletal disease, skin disease, anti-dsDNA, and erythrocyte sedimentation rate, and lower levels of complement. However, changes in BAFF or IFN gene signatures were not associated with changes in disease activity. Similar associations were seen between the LDG gene signature and disease activity. However, when LDG increased, complement tended to increase. Patients with high levels of plasma cell gene signature tended to have higher levels of anti-dsDNA and lower levels of complement. However, unlike the other gene signatures, changes in plasma cell gene signature significantly coincided with changes in anti-dsDNA and complement.ConclusionsThe gene expression signatures were relatively stable within patients over time. BAFF and interferon gene expression were markers of patients with generally higher disease activity, but changes in these gene signatures did not coincide with changes in disease activity. Plasma Cell gene signature expression tracked with the traditional SLE serologic markers of anti-dsDNA and complement.

Highlights

  • We assessed the stability of B-cell activating factor (BAFF), interferon, plasma cell and low-density granulocytes (LDG) neutrophil gene expression signatures over time, and whether changes in expression coincided with changes in systemic lupus erythematosus (SLE) disease activity

  • Multiple gene expression signatures have been identified in systemic lupus erythematosus (SLE), including interferon (IFN) [1,2,3], B-cell activating factor (BAFF) [4], low-density granulocytes (LDG) [5], and plasma cell (PC) [6]

  • The Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [28, 29] as well as the Physician Global Assessment (PGA) [30] were completed at each visit

Read more

Summary

Introduction

We assessed the stability of BAFF, interferon, plasma cell and LDG neutrophil gene expression signatures over time, and whether changes in expression coincided with changes in SLE disease activity. Multiple gene expression signatures have been identified in systemic lupus erythematosus (SLE), including interferon (IFN) [1,2,3], B-cell activating factor (BAFF) [4], low-density granulocytes (LDG) [5], and plasma cell (PC) [6]. The potential of the IFN-alpha gene signature to predict change in disease activity over time is uncertain. Petri et al found little change in the IFN-response scores (calculated based on the expression of three IFNα-regulated genes) over time within individual patients [10]. Chiche et al recently identified IFN signatures that are variable over time in single patients [11]. They found a variable IFN signature, not restricted to IFN-alpha, and driven by IFN-beta and gamma

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call